Exhibit 99.1 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 25, 2026: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innova ...

NEWS Exhibit 99.1 Tara Kurian SVP, IR, FP&A, and International (813) 830-5311 Bloomin' Brands Announces 2025 Q4 Financial Results Provides Full Year 2026 Financial Outlook TAMPA, Fla., February 25, 2026 - Bloomin' Brands, Inc. (Nasdaq: BLMN) today reported results for the fourth quarter 2025 ("Q4 2025") and the fiscal year ended December 28, 2025 ("Fiscal Year 2025") compared to the fourth quarter 2024 ("Q4 2024") and the fiscal year ended December 29, 2024 ("Fiscal Year 2024"). The following table reconcil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) (Address of Principal Executive Offices) ...

Exhibit 99.1 Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update SALT LAKE CITY, February 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq : RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025. Recursion will host an earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT from Recursion's X ...

EXHIBIT 99.1 Aspen Aerogels, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights $158.6 million year-end cash balance; $37.6 million GM commercial settlement payment expected in Q1 2026 North Sea subsea pipeline award and continued European OEM program progress Initiated a strategic review to strengthen long-term competitive positioning NORTHBOROUGH, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology ...

CIRCLE REPORTS FOURTH QUARTER AND FULL FISCAL YEAR 2025 FINANCIAL RESULTS NEW YORK – FEBRUARY 25, 2026 — Circle Internet Group, Inc. (NYSE: CRCL) today announced results for the fourth quarter and full fiscal year 2025. Fourth Quarter Highlights (Q4'25 vs. Q4'24) Full Year Financial Highlights (FY25 vs. FY24) Business Highlights . USDC in circulation of $75.3 billion at year end grew 72%; USDC onchain transaction volume in Q4'25 of $11.9 trillion, up 247% Total revenue and reserve income in Q4'25 of $770 mi ...

Exhibit 99.1 Dividend Declaration The Company's Board of Trustees has declared a first quarter 2026 dividend of $0.77 per share to shareholders of record as of March 31, 2026, payable on or about April 24, 2026. Quarterly Investor Call Details Blackstone Secured Lending Fund will host its conference call today at 9:30 a.m. ET to discuss results. To register for the webcast, please use the following link: https://event.webcasts.com/starthere.jsp?ei=1748261&tp_key=5d0010fc74 Blackstone Secured Lending Fund 34 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026 (February 24, 2026) SHOE CARNIVAL, INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) Indiana 0-21360 35-1736614 (Commission File Number) (IRS Employer Identification No.) 1800 Innovation Point, 5th Floor Fort Mill, SC (A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number: 001-39630 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) (IRS Employer Identification No.) Cayman Islands 98-1711963 (State or Other Jurisdiction of Incorporation) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 10-K _______________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File ...